Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-118256
Filing Date
2024-10-29
Accepted
2024-10-29 16:20:23
Documents
68
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q sage-20240930.htm   iXBRL 10-Q 2964008
2 EX-31.1 sage-ex31_1.htm EX-31.1 11225
3 EX-31.2 sage-ex31_2.htm EX-31.2 11204
4 EX-32.1 sage-ex32_1.htm EX-32.1 9299
5 GRAPHIC img94128167_0.jpg GRAPHIC 409700
  Complete submission text file 0000950170-24-118256.txt   12008309

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT sage-20240930.xsd EX-101.SCH 1352211
71 EXTRACTED XBRL INSTANCE DOCUMENT sage-20240930_htm.xml XML 2145699
Mailing Address 55 CAMBRIDGE PARKWAY CAMBRIDGE MA 02142
Business Address 55 CAMBRIDGE PARKWAY CAMBRIDGE MA 02142 617-299-8380
Sage Therapeutics, Inc. (Filer) CIK: 0001597553 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36544 | Film No.: 241406008
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)